✅ No sanctions, screening, insolvency or control red flags found in the public sources we cover. (Absence of a flag is not a guarantee — see methodology.)
INNATE PHARMA
5599 · RC 424365336 · Active since 1999
Overview
INNATE PHARMA is a 5599 registered , France, since 1999. The company operates in the 7211 sector. With reported revenue of 17.8M EUR in 2024. Its TraceComp score of 73 (B+) indicates moderate risk with some areas to watch. With 26 years of operations, the company has an established track record in its market.
Company Information
- Registration Number
- 424365336
- Legal Form
- 5599
- Registered
- 1999-09-23
Financial Profile
Latest filed accounts: FY 2024
Multi-year financials & ratios
5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Officers & Management
11 officers/directors on file — names, roles, appointment & resignation dates.
| Name | Role | Status |
|---|---|---|
| IRINA STAATZ GRANZER | role 51 | Current |
What’s in the full report
- Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
- Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
- Insolvency & legal events — collective proceedings and adverse filings (where on record)
- Charges & secured lending — registered charges and the creditors entitled (where filed)
- Sanctions & screening — company-level watchlist & adverse signals
- Sector benchmark & peers — how the company compares to its sector and nearest peers
- Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Research Output
Active research organization. 900 publications · 161,262 citations · h-index 206 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Immunology and Microbiology (70%) · Medicine (30%).
See full research profile — top researchers & publications →
Source: OpenAlex (CC0). Objective publication & citation counts.
EU Funding
EU-funded innovation. Participated in 1 EU research project, receiving €182,553 in EU contributions (CORDIS — Horizon Europe / Horizon 2020).
Source: CORDIS (EU Open Data, CC-BY). Cumulative EC contribution across the company’s projects.
Patent Portfolio
Active patent holder. 93 patents · 88 active · 93 granted in the USPTO/EPO record.
See full patent portfolio — most-cited inventions & inventors →
Source: USPTO / EPO open patent data. Objective bibliographic counts.
Risk Signals
No adverse legal events have been recorded for this company.
- Revenue down 68% year-on-year
- Net loss reported in FY 2024
- Altman Z-Score in the distress zone — elevated insolvency risk on the model
Data Sources & Freshness
Data sourced from: bulk register.